Association between glucocorticoids treatment and viral clearance delay in patients with COVID-19: A systematic review and meta-analysis

BMC Infectious DiseasesLi J, Liao X, Zhou Y, et al. | October 19, 2021

Advertisement

COVID-19 patients taking high doses or medium doses of glucocorticoids showed delay in viral clearance, whereas those taking low doses did not.

  • From Medline, Embase, EBSCO, ScienceDirect, Web of Science, Cochrane Library, and ClinicalTrials.gov, researchers identified a total of 38 studies with a total of 9,572 patients for inclusion.

  • Moderate-quality evidence suggested delayed viral clearance in COVID-19 patients in correlation with receiving glucocorticoids treatment.

  • Subgroup analyses revealed significant risk of viral clearance delay both for COVID-19 patients being mild or moderate ill, and for patients of being severe or critical ill.

  • The risk appeared significantly increased for patients taking high doses or medium doses.

Read the full article on BMC Infectious Diseases

Advertisement